

Enantioselective Construction of Spiro-1,3-indandiones with Three Stereocenters via Organocatalytic Michael-Aldol Reaction of 2-Arylideneindane-1,3-diones and Nitro Aldehydes

Jindian Duan, Jing Cheng and Pengfei Li*

Department of Chemistry, South University of Science and Technology of China, Shenzhen, Guangdong, 518055, P. R. China; Fax: (+86) 755-88018304.
E-mail: lipf@sustc.edu.cn or flyli1980@gmail.com.

Supporting Information

Contents

Experimental section	S2
General	S2
Compounds characterization	S3
References	S7
NMR Spectra of compounds	S8
HPLC chromatograms	S24
Crystal Structure and data for compound 3ea	S40

Experimental section


General

All reactions were carried out with dry, freshly distilled solvents in anhydrous conditions. Toluene and THF were distilled from sodium, while dichloromethane was distilled from CaH₂ immediately prior to use. All chemicals were used without further purification as commercially available unless otherwise noted. All reactions were performed under an atmosphere of dry nitrogen. Thin-layer chromatography (TLC) was performed on silica gel plates (60F-254) using UV-light (254 and 365 nm). Flash chromatography was conducted on silica gel (300–400 mesh). NMR (400 MHz for ¹H NMR, 100 MHz for ¹³C NMR) spectra were recorded in CDCl₃ or Acetone with TMS as the internal standard. Chemical shifts are reported in ppm and coupling constants are given in Hz. Data for ¹H NMR are recorded as follows: chemical shift (ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, quarter; m, multiplet), coupling constant (Hz), integration. Data for ¹³C NMR are reported in terms of chemical shift (δ, ppm). High resolution mass spectral (HRMS) analyses were measured using ESI techniques. Melting points were determined in a hanon auto melting point system (MP 450).

A variety of 2-arylidene-1,3-indandiones **1** were synthesized via Knoevenagel reactions as reported in the literature.¹ 4-nitrobutanal and 3-nitropropanal were prepared using general procedures reported in the literature.² All the organocatalysts were purchased from Daicel Chiral Technologies (China) Co., LTD.


General procedure for the enantioselective construction of spiro-1,3-indandiones

Procedure A:



To a stirred solution of 2-arylidene-1,3-indandiones **1** (0.2 mmol), 5 Å MS (30 mg) and catalyst **VI** (0.02 mmol) in dichloromethane (2.0 mL) was added 4-nitrobutanal **2a** (0.24 mmol) and then stirred for 12 h at room temperature. After removal of the solvent, the crude residue was purified by column chromatography (petroleum ether/acetone 4/1 v/v) on silica gel to give the corresponding product.


Procedure B:



To a stirred solution of 2-arylidene-1,3-indandiones **1** (0.2 mmol), 5 Å MS (30 mg) and catalyst **VI** (0.02 mmol) in dichloromethane (2.0 mL) was added 3-nitropropanal **2b** (0.24 mmol) and then stirred for 72 h at room temperature. After removal of the solvent, the crude residue was purified by column chromatography (petroleum ether/acetone 4/1 v/v) on silica gel to give the corresponding product.


Compounds characterization

(2R,3R,6R)-6-Hydroxy-3-nitro-2-phenylspiro[cyclohexane-1,2'-indene]-1',3'-dione (**3aa**)




Prepared according to general procedure A to afford **3aa** (58 mg, 83 % yield) as a white solid; m.p. 203-205 °C; $[\alpha]_D^{22} = -91.4$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, Acetone- D_6) δ 7.85-7.72(m, 4H), 7.07-6.97 (m, 5H), 5.89-5.83 (m, 1H), 4.69 (d, $J = 4.4$ Hz, 1H), 4.42-4.37 (m, 1H), 3.79 (d, $J = 12.0$ Hz, 1H), 2.67-2.61 (m, 1H), 2.53-2.43 (m, 1H), 2.34-2.23 (m, 1H), 2.17-2.11 (m, 1H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 202.2, 200.8, 143.3, 142.8, 135.8, 135.7, 134.3, 128.6, 128.4, 128.0, 122.4, 122.2, 84.8, 73.2, 63.2, 49.4, 28.7; HRMS (ESI): m/z calcd for $\text{C}_{20}\text{H}_{17}\text{NNaO}_5$ $[\text{M}+\text{Na}]$ 374.1004, Found 374.1006; HPLC conditions: Daicel Chiralpak OD-H column, n -hexane/2-propanol = 85/15, flow rate = 1.0 mL/min, $\lambda = 254$ nm, retention time: t_R (minor) = 17.1 min, t_R (major) = 20.1 min, 90% ee.

(2R,3R,6R)-2-(4-Fluorophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione (**3ba**)




Prepared according to general procedure A to afford **3ba** (59 mg, 80 % yield) as a white solid; m.p. 195-197 °C; $[\alpha]_D^{22} = -95.8$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, Acetone- D_6) δ 7.87-7.76(m, 4H), 7.09-7.06 (m, 2H), 6.87-6.83 (m, 2H), 5.86-5.79 (m, 1H), 4.72 (d, $J = 4.0$ Hz, 1H), 4.42-4.37 (m, 1H), 3.80 (d, $J = 12.0$ Hz, 1H), 2.67-2.62 (m, 1H), 2.52-2.41 (m, 1H), 2.34-2.27 (m, 1H), 2.17-2.13 (m, 1H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 207.3, 205.9, 168.5($J_{\text{C-F}} = 244.1$ Hz), 148.5, 147.9, 141.2, 141.1, 135.8, 135.7($J_{\text{C-F}} = 3.0$ Hz), 127.6($J_{\text{C-F}} = 6.7$ Hz), 127.5, 120.5 ($J_{\text{C-F}} = 20.7$ Hz), 90.1, 78.3, 68.4, 53.8, 34.7; HRMS (ESI): m/z calcd for $\text{C}_{20}\text{H}_{16}\text{FNNaO}_5$ $[\text{M}+\text{Na}]$ 392.0910, Found 392.0912; HPLC conditions: Daicel Chiralpak IB-3 column, n -hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, $\lambda = 254$ nm, retention time: t_R (major) = 9.3 min, t_R (minor) = 13.4 min, 89% ee.

(2R,3R,6R)-2-(4-Bromophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione (**3ca**)



Prepared according to general procedure A to afford **3ca** (64 mg, 75 % yield) as a white solid; m.p. 232-235 °C; $[\alpha]_D^{22} = -78.5$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.82-7.81(m, 1H), 7.72-7.66 (m, 3H), 7.13 (d, $J = 8.4$ Hz, 2H), 6.89 (d, $J = 8.4$ Hz, 2H), 5.82-5.77 (m, 1H), 4.40-4.36 (m, 1H), 3.79 (d, $J = 12.0$ Hz, 1H), 2.65-2.61 (m, 1H), 2.53-2.49 (m, 1H), 2.23-2.19 (m, 1H), 2.15-2.09 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 201.9, 200.9, 143.1, 142.5, 136.1, 135.9, 132.4, 131.8, 130.2, 122.9, 122.7, 122.5, 84.1, 73.3, 62.9, 48.8, 29.6, 28.6; HRMS (ESI): m/z calcd for $\text{C}_{20}\text{H}_{16}\text{BrNNaO}_5$ $[\text{M}+\text{Na}]$ 452.0110, Found 452.0109; HPLC conditions: Daicel Chiralpak IB-3 column, n -hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, $\lambda = 254$ nm, retention time: t_R (major) = 9.9 min, t_R (minor) = 14.3 min, 86% ee.


(2R,3R,6R)-6-Hydroxy-3-nitro-2-(p-tolyl)spiro[cyclohexane-1,2'-indene]-1',3'-dione (**3da**)



Prepared according to general procedure A to afford **3da** (55 mg, 76 % yield) as a white solid; m.p. 228-230 °C; $[\alpha]_D^{22} = -82.8$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, Acetone- D_6) δ 7.87-7.73 (m, 4H), 6.92-6.84 (m, 4H), 5.86-5.79 (m, 1H), 4.65 (d, $J = 4.4$ Hz, 1H), 4.39-4.34 (m, 1H), 3.75 (d, $J = 11.6$ Hz, 1H), 2.65-2.59 (m, 1H), 2.48-2.40 (m, 1H), 2.32-2.25 (m, 1H), 2.15-2.09 (m, 1H), 2.04 (s, 3H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 202.3, 200.8, 143.4, 142.9,


137.6, 135.8, 135.7, 131.3, 128.9, 128.5, 122.4, 122.2, 85.0, 73.2, 73.1, 63.2, 48.9, 28.7, 19.9; HRMS (ESI): m/z calcd for $C_{21}H_{19}NNaO_5$ $[M+Na]$ 388.1161, Found 388.1156; HPLC conditions: Daicel Chiralpak IB-3 column, *n*-hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, λ = 254 nm, retention time: t_R (major) = 8.4 min, t_R (minor) = 11.8 min, 86% ee.

(2R,3R,6R)-6-Hydroxy-2-(4-methoxyphenyl)-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione (3ea)




Prepared according to general procedure A to afford **3ea** (61 mg, 80 % yield) as a white solid; m.p. 230-232 °C; $[\alpha]_D^{22} = -40.9$ ($c = 1.0$, $CHCl_3$); 1H NMR (500 MHz, $CDCl_3$) δ 7.79-7.78 (m, 1H), 7.68-7.58 (m, 3H), 6.90 (d, $J = 8.5$ Hz, 2H), 6.50 (d, $J = 8.5$ Hz, 2H), 5.79-5.74 (m, 1H), 4.38-4.36 (m, 1H), 3.74 (d, $J = 12.0$ Hz, 1H), 3.56 (s, 3H), 2.61-2.56 (m, 1H), 2.53-2.47 (m, 1H), 2.24-2.14 (m, 2H), 2.11-2.07 (m, 1H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 202.2, 201.4, 159.1, 143.2, 142.6, 135.7, 135.6, 129.6, 125.2, 122.8, 122.6, 113.9, 84.5, 73.2, 63.3, 54.9, 48.8, 29.6, 28.6; HRMS (ESI): m/z calcd for $C_{21}H_{19}NNaO_6$ $[M+Na]$ 404.1110, Found 404.1112; HPLC conditions: Daicel Chiralpak IB-3 column, *n*-hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, λ = 254 nm, retention time: t_R (major) = 11.6 min, t_R (minor) = 16.5 min, 88% ee.

(2R,3R,6R)-2-(3-Bromophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione (3fa)



Prepared according to general procedure A to afford **3fa** (69 mg, 80 % yield) as a white solid; m.p. 226-228 °C; $[\alpha]_D^{22} = -74.7$ ($c = 1.0$, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$) δ 7.85-7.83 (m, 1H), 7.75-7.65 (m, 3H), 7.15-7.09 (m, 2H), 6.97-6.95 (m, 1H), 6.89-6.86 (m, 1H), 5.81-5.74 (m, 1H), 4.43-4.37 (m, 1H), 3.78 (d, $J = 12.0$ Hz, 1H), 2.67-2.61 (m, 1H), 2.56-2.49 (m, 1H), 2.28-2.19 (m, 1H), 2.17-2.11 (m, 1H), 1.89 (d, $J = 5.2$ Hz, 1H); ^{13}C NMR (400 MHz, $CDCl_3$) δ 201.6, 200.7, 143.1, 142.4, 135.9, 135.8, 135.6, 131.5, 130.1, 122.9, 122.7, 122.6, 83.9, 73.2, 62.8, 48.9, 29.6, 28.7; HRMS (ESI): m/z calcd for $C_{20}H_{16}BrNNaO_5$ $[M+Na]$ 452.0110, Found 452.0108; HPLC conditions: Daicel Chiralpak IB-3 column, *n*-hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, λ = 254 nm, retention time: t_R (major) = 10.0 min, t_R (minor) = 13.3 min, 77% ee.


(2R,3R,6R)-6-Hydroxy-3-nitro-2-(3-nitrophenyl)spiro[cyclohexane-1,2'-indene]-1',3'-dione (3ga)



Prepared according to general procedure A to afford **3ga** (54 mg, 68 % yield) as a white solid; m.p. 241-242 °C; $[\alpha]_D^{22} = -75.4$ ($c = 1.0$, $CHCl_3$); 1H NMR (400 MHz, Acetone- D_6) δ 7.93-7.78 (m, 6H), 7.50-7.44 (m, 2H), 5.94-5.93 (m, 1H), 4.82 (m, 1H), 4.44 (m, 1H), 4.00-3.97 (m, 1H), 2.72-2.69 (m, 1H), 2.49-2.34 (m, 2H), 2.20-2.17 (m, 1H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 201.8, 200.4, 147.9, 143.2, 142.6, 136.6, 136.3, 136.2, 134.9, 130.1, 123.1, 122.6, 122.4, 84.5, 73.2, 63.1, 48.7; HRMS (ESI): m/z calcd for $C_{20}H_{16}N_2NaO_7$ $[M+Na]$ 419.0855, Found 419.0852; HPLC conditions: Daicel Chiralpak IB-3 column, *n*-hexane/2-propanol = 80/20, flow rate = 1.5 mL/min, λ = 254 nm, retention time: t_R (major) = 10.6 min, t_R (minor) = 13.8 min, 66% ee.

(2S,3R,6R)-2-(2-Chlorophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione (3ha)


Prepared according to general procedure A to afford **3ha** (56 mg, 73 % yield) as a white solid; m.p. 206-208 °C; $[\alpha]_D^{22} = -68.7$ ($c = 1.0$, $CHCl_3$); 1H NMR (400 MHz, Acetone- D_6) δ 7.94-7.92 (m, 1H), 7.87-7.73 (m, 4H), 7.26-7.21 (m, 2H), 7.03-7.01 (m, 2H), 5.78-5.71 (m, 1H), 4.81 (d, $J =$



4.0 Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 4.47-4.42 (m, 1H), 2.67-2.63 (m, 1H), 2.57-2.44 (m, 1H), 2.38-2.28 (m, 1H), 2.19-2.15 (m, 1H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 202.8, 198.9, 143.4, 142.7, 135.9, 135.8, 134.6, 132.3, 130.4, 129.5, 128.4, 127.1, 122.5, 122.4, 85.6, 73.3, 73.1, 62.3, 44.2, 28.5; HRMS (ESI): m/z calcd for $\text{C}_{20}\text{H}_{16}\text{ClNNaO}_5$ [$\text{M}+\text{Na}$] 408.0615, Found 408.0612;

HPLC conditions: Daicel Chiralpak IB-3 column, n -hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, λ = 254 nm, retention time: t_R (major) = 11.7 min, t_R (minor) = 13.6 min, 86% ee.


(2S,3R,6R)-2-(2-Bromophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione (3ia)



Prepared according to general procedure A to afford **3ia** (64 mg, 75 % yield) as a white solid; m.p. 225-227 °C; $[\alpha]_D^{22}$ = -35.4 (c = 1.0, CHCl_3); ^1H NMR (400 MHz, Acetone- D_6) δ 7.94 (d, J = 7.6 Hz, 1H), 7.88-7.73 (m, 3H), 7.41 (dd, J = 8.0, 1.2 Hz, 1H), 7.25 (dd, J = 8.0, 1.2 Hz, 1H), 7.07-7.03 (m, 1H), 6.96-6.91 (m, 1H), 5.77-5.70 (m, 1H), 4.76 (d, J = 4.4 Hz, 1H), 4.55 (d, J = 12.0 Hz, 1H),

4.48-4.42 (m, 1H), 2.67-2.62 (m, 1H), 2.58-2.48 (m, 1H), 2.39-2.28 (m, 1H), 2.20-2.14 (m, 1H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 202.8, 198.8, 143.5, 142.8, 135.9, 135.8, 133.9, 129.7, 128.5, 127.6, 125.6, 122.5, 122.4, 85.6, 73.3, 62.3, 46.9, 29.5, 28.5; HRMS (ESI): m/z calcd for $\text{C}_{20}\text{H}_{16}\text{BrNNaO}_5$ [$\text{M}+\text{Na}$] 452.0110, Found 452.0108; HPLC conditions: Daicel Chiralpak IB-3 column, n -hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, λ = 254 nm, retention time: t_R (major) = 9.8 min, t_R (minor) = 15.3 min, 86% ee.


(2R,3R,6R)-2-(Furan-2-yl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione (3ja)



Prepared according to general procedure A to afford **3ja** (57 mg, 84 % yield) as a white solid; m.p. 135-137 °C; $[\alpha]_D^{22}$ = -60.1 (c = 1.0, CHCl_3); ^1H NMR (400 MHz, Acetone- D_6) δ 7.91-7.84 (m, 4H), 7.07 (d, J = 1.2 Hz, 1H), 6.03-5.97 (m, 2H), 5.70-5.63 (m, 1H), 4.65 (d, J = 4.4 Hz, 1H), 4.38-4.33 (m, 1H), 3.93 (d, J = 8.0 Hz, 1H), 2.63-2.57 (m, 1H), 2.47-2.39 (m, 1H), 2.31-2.23 (m, 1H),

2.14-2.09 (m, 1H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 200.9, 200.3, 148.5, 143.1, 142.7, 142.5, 135.8, 135.6, 122.5, 122.4, 110.1, 108.8, 84.1, 72.6, 61.4, 43.2, 29.2, 28.4; HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{15}\text{NNaO}_6$ [$\text{M}+\text{Na}$] 364.0797, Found 364.0795; HPLC conditions: Daicel Chiralpak IB-3 column, n -hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, λ = 254 nm, for major diastereomer: retention time: t_R (major) = 7.9 min, t_R (minor) = 10.1 min, 88% ee, 97.8:2.1 dr.


(2R,3R,6R)-6-Hydroxy-3-nitro-2-(thiophen-2-yl)spiro[cyclohexane-1,2'-indene]-1',3'-dione (3ka)



Prepared according to general procedure A to afford **3ka** (43 mg, 61 % yield) as a white solid; m.p. 151-153 °C; $[\alpha]_D^{22}$ = -81.7 (c = 1.0, CHCl_3); ^1H NMR (400 MHz, Acetone- D_6) δ 7.91-7.82 (m, 4H), 7.09 (d, J = 5.2 Hz, 1H), 6.73-6.67 (m, 2H), 5.75-5.68 (m, 1H), 4.75 (d, J = 5.2 Hz, 1H), 4.39-4.34 (m, 1H), 4.10 (d, J = 11.6 Hz, 1H), 2.65-2.59 (m, 1H), 2.45-2.38 (m, 1H),


2.32-2.25 (m, 1H), 2.16-2.09 (m, 1H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 202.1, 200.7, 143.5, 142.9, 136.0, 135.9, 135.8, 127.4, 126.5, 125.5, 122.5, 122.3, 86.4, 73.0, 63.3, 44.5, 29.5, 28.5; HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{15}\text{NNaO}_5\text{S}$ [$\text{M}+\text{Na}$] 380.0569, Found 380.0566; HPLC conditions: Daicel Chiralpak IA-3 column, n -hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, λ = 254 nm, retention time: t_R (minor) = 11.4 min, t_R (major) = 12.2 min, 74% ee.

(2R,3R,5R)-5-Hydroxy-3-nitro-2-phenylspiro[cyclopentane-1,2'-indene]-1',3'-dione (3ab)




Prepared according to general procedure B to afford **3ab** (63mg, 94 % yield) as a pale off-white sticky oil; $[\alpha]_D^{22} = -58.7$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, Acetone- D_6) δ 7.94-7.91 (m, 1H), 7.89-7.86 (m, 3H), 7.23-7.09 (m, 5H), 6.11-6.05 (m, 1H), 5.08 (s, 1H), 5.05-5.00 (m, 1H), 4.31 (d, $J = 9.6$ Hz, 1H), 2.97-2.92 (m, 2H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 199.8, 199.5, 143.2, 142.9, 136.4, 136.1, 134.3, 128.7, 128.2, 128.1, 122.8, 122.7, 86.1, 76.9, 70.3, 53.5, 37.2; HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{15}\text{NNaO}_5$ [$\text{M}+\text{Na}$] 360.0848, Found 360.0842; HPLC conditions: Daicel Chiralpak OD-H column, n -hexane/2-propanol = 80/20, flow rate = 1.0 mL/min, $\lambda = 254$ nm, retention time: t_R (major) = 11.4 min, t_R (minor) = 14.4 min, 90% ee.

(2R,3R,5R)-2-(4-Fluorophenyl)-5-hydroxy-3-nitrospiro[cyclopentane-1,2'-indene]-1',3'-dione (3bb)




Prepared according to general procedure B to afford **3bb** (64 mg, 90 % yield) as a pale off-white sticky oil; $[\alpha]_D^{22} = -84.2$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, Acetone- D_6) δ 7.96-7.89 (m, 4H), 7.29-7.25 (m, 2H), 6.99-6.94 (m, 2H), 6.08-6.02 (m, 1H), 5.10 (s, 1H), 5.03-4.99 (m, 1H), 4.31 (d, $J = 9.6$ Hz, 1H), 2.97-2.92 (m, 2H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 199.7, 199.5, 163.5 ($J_{\text{C-F}} = 243.7$ Hz), 143.1 ($J_{\text{C-F}} = 15.4$ Hz), 136.5, 136.2, 130.5 ($J_{\text{C-F}} = 2.8$ Hz), 130.3 ($J_{\text{C-F}} = 8.5$ Hz), 122.9, 122.7, 115.5, 115.3, 86.2, 76.9, 70.3, 52.6, 37.1; HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{14}\text{FNNaO}_5$ [$\text{M}+\text{Na}$] 378.0754, Found 378.0751; HPLC conditions: Daicel Chiralpak IB-3 column, n -hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, $\lambda = 254$ nm, retention time: t_R (major) = 9.0 min, t_R (minor) = 11.1 min, 87% ee.

(2R,3R,5R)-5-Hydroxy-3-nitro-2-(p-tolyl)spiro[cyclopentane-1,2'-indene]-1',3'-dione (3db)




Prepared according to general procedure B to afford **3db** (43 mg, 62 % yield) as a pale off-white sticky oil; $[\alpha]_D^{22} = -59.7$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, Acetone- D_6) δ 7.94-7.90 (m, 1H), 7.89-7.83 (m, 3H), 7.11-7.08 (m, 2H), 6.97-6.95 (m, 2H), 6.06-6.00 (m, 1H), 5.06-4.99 (m, 2H), 4.28 (d, $J = 10.0$ Hz, 1H), 2.95-2.90 (m, 2H), 2.12-2.10 (m, 3H); ^{13}C NMR (101 MHz, Acetone- D_6) δ 199.9, 199.6, 143.2, 143.0, 137.8, 136.4, 136.1, 131.2, 129.3, 128.1, 122.8, 122.7, 86.4, 76.9, 70.3, 53.3, 37.2, 20.00; HRMS (ESI): m/z calcd for $\text{C}_{20}\text{H}_{17}\text{NNaO}_5$ [$\text{M}+\text{Na}$] 374.1004, Found 374.1007; HPLC conditions: Daicel Chiralpak IB-3 column, n -hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, $\lambda = 254$ nm, retention time: t_R (major) = 7.9 min, t_R (minor) = 9.5 min, 87% ee.

(2R,3R,5R)-2-(3-Bromophenyl)-5-hydroxy-3-nitrospiro[cyclopentane-1,2'-indene]-1',3'-dione (3fb)



Prepared according to general procedure B to afford **3fb** (63 mg, 76 % yield) as a pale off-white sticky oil; $[\alpha]_D^{22} = -64.2$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, Acetone- D_6) δ 7.96-7.95 (m, 1H), 7.92-7.90 (m, 3H), 7.48-7.44 (m, 1H), 7.33-7.31 (m, 1H), 7.25-7.23 (m, 1H), 7.16-7.13 (m, 1H), 6.11-6.07 (m, 1H), 5.12 (s, 1H), 5.04-4.99 (m, 1H), 4.32 (d, $J = 10.0$ Hz, 1H), 2.99-2.94 (m, 2H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 199.5, 199.3, 143.1, 142.9, 137.2, 136.6, 136.3, 131.2, 131.1, 130.6, 127.3, 122.9, 122.7, 122.2, 85.7, 77.0, 70.4, 52.5, 36.9; HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{14}\text{BrNNaO}_5$ [$\text{M}+\text{Na}$] 437.9953, Found 437.9947; HPLC conditions: Daicel Chiralpak IB-3 column, n -hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, $\lambda = 254$ nm, retention time: t_R (major) = 8.9 min, t_R (minor) = 10.3 min, 68% ee.

(2R,3R,5R)-5-Hydroxy-3-nitro-2-(3-nitrophenyl)spiro[cyclopentane-1,2'-indene]-1',3'-dione (3gb)





Prepared according to general procedure B to afford **3gb** (55 mg, 72 % yield) as a pale off-white sticky oil; $[\alpha]_D^{22} = -59.5$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, $\text{Acetone-}D_6$) δ 8.14 (s, 1H), 8.05-8.03 (m, 1H), 7.97-7.88 (m, 4H), 7.71-7.69 (m, 1H), 7.56-7.52 (m, 1H), 6.24-6.18 (m, 1H), 5.18 (s, 1H), 5.06-5.02 (m, 1H), 4.50 (d, $J = 9.6$ Hz, 1H), 3.04-2.96 (m, 2H); ^{13}C NMR (100MHz, $\text{Acetone-}D_6$) δ 199.3, 199.2, 148.3, 143.0, 142.9, 137.0, 136.7, 136.3, 134.8, 130.1, 123.0, 123.0, 122.8, 85.5, 77.1, 70.5, 52.1, 36.8; HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{14}\text{N}_2\text{NaO}_7$ $[\text{M}+\text{Na}]$ 405.0699, Found 405.0697; HPLC conditions: Daicel Chiralpak IB-3 column, n -hexane/2-propanol = 85/15, flow rate = 1.5 mL/min, $\lambda = 254$ nm, retention time: t_R (major) = 18.9 min, t_R (minor) = 23.7 min, 65% ee.

References


- 1 E. Li, Y. Huang, L. Liang and P. Xie, *Org. Lett.*, 2013, **15**, 3138.
- 2 (a) L. E. Blidi, D. Crestia, E. Gallienne, C. Demuynck, J. Bolte and M. Lemaire, *Tetrahedron: Asymmetry*, 2004, **15**, 2951; (b) L. Hu, F. Xiong, X. Chen, W. Chen, Q. He and F. Chen, *Tetrahedron: Asymmetry*, 2013, **24**, 207.

NMR Spectra of compounds


(2R,3R,6R)-6-Hydroxy-3-nitro-2-phenylspiro[cyclohexane-1,2'-indene]-1',3'-dione(3aa)





(2R,3R,6R)-2-(4-Fluorophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ba)




(2R,3R,6R)-2-(4-Bromophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ca)





(2R,3R,6R)-6-Hydroxy-3-nitro-2-(p-tolyl)spiro[cyclohexane-1,2'-indene]-1',3'-dione(3da)





(2R,3R,6R)-6-Hydroxy-2-(4-methoxyphenyl)-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ea)





(2R,3R,6R)-2-(3-Bromophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3fa)





(2R,3R,6R)-6-Hydroxy-3-nitro-2-(3-nitrophenyl)spiro[cyclohexane-1,2'-indene]-1',3'-dione(3ga)




(2S,3R,6R)-2-(2-Chlorophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ha)




(2S,3R,6R)-2-(2-Bromophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ia)




(2R,3R,6R)-2-(Furan-2-yl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ja)







(2R,3R,6R)-6-Hydroxy-3-nitro-2-(thiophen-2-yl)spiro[cyclohexane-1,2'-indene]-1',3'-dione(3ka)




(2R,3R,5R)-5-Hydroxy-3-nitro-2-phenylspiro[cyclopentane-1,2'-indene]-1',3'-dione(3ab)








(2R,3R,5R)-2-(4-Fluorophenyl)-5-hydroxy-3-nitrospiro[cyclopentane-1,2'-indene]-1',3'-dione(3bb)







(2R,3R,5R)-5-Hydroxy-3-nitro-2-(p-tolyl)spiro[cyclopentane-1,2'-indene]-1',3'-dione(3db)



(2R,3R,5R)-2-(3-Bromophenyl)-5-hydroxy-3-nitrospiro[cyclopentane-1,2'-indene]-1',3'-dione(3fb)




(2R,3R,5R)-5-Hydroxy-3-nitro-2-(3-nitrophenyl)spiro[cyclopentane-1,2'-indene]-1',3'-dione(3gb)




HPLC chromatograms

(2R,3R,6R)-6-Hydroxy-3-nitro-2-phenylspiro[cyclohexane-1,2'-indene]-1',3'-dione(3aa)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.253	BB	0.4368	2.55332e4	853.97699	49.7900
2	19.021	BB	0.5346	2.57486e4	704.13849	50.2100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.136	BB	0.4625	1438.18164	45.53844	5.0921
2	20.148	BB	0.5718	2.68051e4	680.17822	94.9079

(2R,3R,6R)-2-(4-Fluorophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ba)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.369	BB	0.3033	4.18816e4	2042.25781	50.2670
2	13.335	BB	0.4758	4.14367e4	1279.43555	49.7330




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.307	BB	0.3345	3.09855e4	1387.46765	94.4788
2	13.397	BB	0.4774	1810.75903	57.81847	5.5212

(2R,3R,6R)-2-(4-Bromophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ca)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.987	BV	0.3415	4.18093e4	1837.11255	50.3319
2	14.065	BB	0.5100	4.12579e4	1191.36108	49.6681




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.974	BV	0.3303	1.04951e4	470.33276	92.9283
2	14.272	BB	0.4374	798.66638	26.21976	7.0717

(2R,3R,6R)-6-Hydroxy-3-nitro-2-(p-tolyl)spiro[cyclohexane-1,2'-indene]-1',3'-dione(3da)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.031	BB	0.2817	9833.81934	522.24817	50.7584
2	12.574	BB	0.4249	9539.96875	330.36652	49.2416




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.434	BV	0.3128	2.59612e4	1198.05847	93.1180
2	11.865	BB	0.3500	1918.68237	82.29803	6.8820

(2R,3R,6R)-6-Hydroxy-2-(4-methoxyphenyl)-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ea)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.445	BB	0.3904	1.18199e4	444.32159	50.8760
2	15.947	BB	0.5723	1.14129e4	293.06638	49.1240




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.570	BB	0.4304	8004.49561	272.70755	93.8807
2	16.482	BB	0.5820	521.75037	13.34822	6.1193

(2R,3R,6R)-2-(3-Bromophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3fa)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.089	BB	0.3576	5.26502e4	2181.50879	50.9125
2	13.200	BB	0.4763	5.07629e4	1565.56897	49.0875




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.001	BB	0.3439	3.11253e4	1306.62756	88.6725
2	13.374	BB	0.4424	3976.11279	132.38905	11.3275

(2R,3R,6R)-6-Hydroxy-3-nitro-2-(3-nitrophenyl)spiro[cyclohexane-1,2'-indene]-1',3'-dione(3ga)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.612	BV	0.3410	1.38061e4	607.71643	49.6401
2	13.635	VB	0.4697	1.40063e4	446.83270	50.3599




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.630	BV	0.3418	1.77828e4	780.46069	82.9432
2	13.855	BB	0.4627	3656.92969	120.28986	17.0568

(2S,3R,6R)-2-(2-Chlorophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ha)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.606	BB	0.2491	5088.10303	307.38098	50.8394
2	13.628	BB	0.2989	4920.08398	244.37735	49.1606




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.707	BB	0.2526	743.25397	45.49549	7.2548
2	13.665	BB	0.3034	9501.74512	470.92419	92.7452

(2S,3R,6R)-2-(2-Bromophenyl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ia)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.707	BB	0.3282	1.10259e4	498.21313	49.8769
2	14.870	BB	0.5441	1.10804e4	295.06595	50.1231




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.798	BB	0.3275	4635.42383	209.99899	92.7230
2	15.288	BB	0.4827	363.79510	10.86412	7.2770

(2R,3R,6R)-2-(Furan-2-yl)-6-hydroxy-3-nitrospiro[cyclohexane-1,2'-indene]-1',3'-dione(3ja)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.852	BV	0.2235	345.51950	22.96283	1.8080
2	7.930	VV	0.2773	9333.17383	487.66599	48.8387
3	9.187	VV	0.3444	390.05984	16.00299	2.0411
4	9.928	VB	0.3370	9041.44238	395.12744	47.3121




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.914	BV	0.2711	8620.12402	467.59308	92.0836
2	9.126	VV	0.3438	200.45915	8.60523	2.1414
3	10.100	VB	0.3882	540.61438	19.82370	5.7751

(2R,3R,6R)-6-Hydroxy-3-nitro-2-(thiophen-2-yl)spiro[cyclohexane-1,2'-indene]-1',3'-dione(3ka)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.340	BV	0.2446	1331.47620	82.36429	49.6108
2	12.230	VB	0.2642	1352.36499	76.52934	50.3892




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.385	BV	0.2634	823.66144	46.33184	13.2814
2	12.256	VB	0.2730	5377.94434	291.81488	86.7186

(2R,3R,5R)-5-Hydroxy-3-nitro-2-phenylspiro[cyclopentane-1,2'-indene]-1',3'-dione(3ab)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.631	BB	0.5133	1220.81396	35.49238	48.0308
2	14.722	BB	0.6557	1320.91846	30.59381	51.9692




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.424	BB	0.4703	3730.86743	119.47281	94.9220
2	14.424	BB	0.6020	199.58965	5.08446	5.0780

(2R,3R,5R)-2-(4-Fluorophenyl)-5-hydroxy-3-nitrospiro[cyclopentane-1,2'-indene]-1',3'-dione(3bb)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.119	BB	0.2607	5562.17725	323.38464	49.7330
2	11.005	BB	0.3080	5621.88965	275.62732	50.2670




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.052	VB	0.2670	1.83256e4	1032.84497	93.3636
2	11.090	BB	0.3061	1302.61731	64.36866	6.6364

(2R,3R,5R)-5-Hydroxy-3-nitro-2-(p-tolyl)spiro[cyclopentane-1,2'-indene]-1',3'-dione(3db)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.904	VB	0.2379	7574.25684	480.55981	52.7329
2	9.372	BB	0.2693	6789.18750	378.37341	47.2671




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.949	BB	0.2449	2144.45166	132.42311	93.2734
2	9.472	BB	0.2617	154.65190	8.60287	6.7266

(2R,3R,5R)-2-(3-Bromophenyl)-5-hydroxy-3-nitrospiro[cyclopentane-1,2'-indene]-1',3'-dione(3fb)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.932	BV	0.2565	1.56476e4	919.64313	49.4185
2	10.242	VB	0.2999	1.60158e4	805.80792	50.5815




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.951	BV	0.2588	3412.71875	198.23868	83.9084
2	10.322	VB	0.3038	654.47711	32.38340	16.0916

(2R,3R,5R)-5-Hydroxy-3-nitro-2-(3-nitrophenyl)spiro[cyclopentane-1,2'-indene]-1',3'-dione(3gb)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	18.781	BB	0.4790	5332.33301	164.12785	49.6093
2	23.577	BB	0.5527	5416.32568	147.38565	50.3907



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	18.974	BB	0.5208	3514.56592	99.80968	82.2950
2	23.702	BB	0.5238	756.12445	18.69752	17.7050

Crystal Structure and data for compound 3ea



Crystal data and structure refinement for compound **3ea**

Identification code	shelx	
Empirical formula	C ₂₁ H ₁₉ N O ₆	
Formula weight	381.37	
Temperature	293(2) K	
Wavelength	1.54187 Å	
Crystal system	Orthorhombic	
Space group	P 21 21 21	
Unit cell dimensions	a = 10.85690(10) Å	α = 90 °
	b = 14.9130(2) Å	β = 90 °
	c = 23.1808(16) Å	γ = 90 °
Volume	3753.2(3) Å ³	
Z	8	
Density (calculated)	1.350 Mg/m ³	
Absorption coefficient	0.831 mm ⁻¹	
F(000)	1600	
Crystal size	0.20 x 0.20 x 0.20 mm ³	
Theta range for data collection	7.034 to 68.581 °	
Index ranges	-12 ≤ h ≤ 13, -17 ≤ k ≤ 17, -27 ≤ l ≤ 27	
Reflections collected	52124	
Independent reflections	6840 [R(int) = 0.0484]	
Completeness to theta = 67.687 °	99.5 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.861 and 0.684	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	6840 / 1 / 512	
Goodness-of-fit on F ²	1.097	
Final R indices [I > 2σ(I)]	R1 = 0.0978, wR2 = 0.2475	
R indices (all data)	R1 = 0.1036, wR2 = 0.2574	
Absolute structure parameter	0.03(7)	
Extinction coefficient	0.0016(6)	
Largest diff. peak and hole	0.735 and -0.302 e.Å ⁻³	